Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity

AIDS

Volumn 20, Issue 17, 2006, Pages 2149-2157

  Peng, Bo ^a   Voltan, Rebecca ^a   Cristillo, Anthony D ^b   Alvord, W Gregory ^c   Davis Warren, Alberta ^a   Zhou, Qifeng ^a   Murthy, Krishna K ^d   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Animal models; CD4; Cellular immunity; Primate; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEF PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN;

ADENOVIRUS 7; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CELLULAR IMMUNITY; CHIMPANZEE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN ADENOVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MEMORY T LYMPHOCYTE; MYRISTYLATION; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE PRODUCTS, NEF; HIV INFECTIONS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; MALE; PAN TROGLODYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750601327     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32801086ee     Document Type: Article

References (50)

1. Joseph AM, Kumar M, Mitra D. Nef: 'Necessary and enforcing factor' in HIV infection. Curr HIV Res 2005; 3:87-94.
2. Wu Y, Marsh JW. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 2001; 293:1503-1506.
3. Fujii Y, Nishino Y, Nakaya T, Tokynaga K, Ikuta K. Expression of human immunodeficiency virus type 1 Nef antigen on the surface of acutely and persistently infected human T cells. Vaccine 1993; 11:1240-1246.
4. Yamada T, Watanabe N, Nakamura T, Iwamoto A. Antibody-dependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface. J Immunol 2004; 172:2401-2406.
5. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991; 350:508-511.
6. Schwartz O, Marechal V, LeGall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996; 2:338-342.
7. Tolstrup M, Ostergaard L, Laursen AL, Pedersen SF, Duch M. HIV/SIV escape from immune surveillance: focus on Nef. Curr HIV Res 2004; 2:141-151.
8. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998; 391:397-401.
9. Swigut T, Alexander L, Morgan J, Lifson J, Mansfield KG, Lang S, et al. Impact of Nef-mediated downregulation of major histocompatibility complex class I on immune response to simian immunodeficiency virus. J Virol 2004; 78:13335-13344.
10. Schindler M, Wurfl S, Benaroch P, Greenough TC, Daniels R, Easterbrook P, et al. Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles. J Virol 2003; 77:10548-10556.
11. Roche PA, Teletski CL, Karp DR, Pinet V, Bakke O, Long EL. Stable surface expression of invariant chain prevents peptide presentation by HLA-DR. EMBO J 1992; 11:2841-2847.
12. Geyer M, Fackler OT, Peterlin BM. Structure-function relationships in HIV-1 Nef. EMBO Rep 2001; 2:580-585.
13. Stumptner-Cuvelette P, Morchoisne S, Dugast M, Le Gall S, Raposo G, Schwartz O, et al. HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proc Natl Acad Sci USA 2001; 98:12144-12149.
14. Peng B, Robert-Guroff M. Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. Immunol Lett 2001; 78:195-200.
15. Peng B, Wang LR, Gomez-Roman VR, Davis-Warren A, Montefiori DC, Kalyanaraman VS, et al. Replicating rather than non-replicating Adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high titer antibodies. J Virol 2005; 79:10200-10209.
16. Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gomez-Roman VR, Wang L, et al. Protection against mucosal SIVmac251 challenge using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 2004; 78:2212-2221.
17. mac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology, in press.
18. Levesque K, Finzi A, Binette J, Cohen EA. Role of CD4 receptor down-regulation during HIV-1 infection. Curr HIV Res 2004; 2:51-59.
19. Rose JJ, Janvier K, Chandrasekhar S, Sekaly RP, Bonifacino JS, Venkatesan S. CD4 down-regulation by HIV-1 and simian immunodeficiency virus (SIV) Nef proteins involves both internalization and intracellular retention mechanisms. J Biol Chem 2005; 280:7413-7426.
20. Shugars DC, Smith MS, Glueck DH, Nantermet PV, Seillier-Moiseiwitsch R, Swanstrom R. Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo. J Virol 1993; 67:4639-4650.
21. Zhao J, Lou Y, Pinczewski J, Malkevitch N, Aldrich K, Kalyanaraman VS, et al. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. Vaccine 2003; 21:4022-4035.
22. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, North Carolina: SAS Institute Inc; 1996.
23. Milliken GA, Johnson DE. Analysis of Messy Data, Volume 1: Designed Experiments. New York: Chapman and Hall; 1992.
24. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-Plus. New York: Springer-Verlag; 2000.
25. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22:745-763.
26. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
27. Harari A, Vallelian F, Pantaleo G. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol 2004; 34:3525-3533.
28. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003; 101:4260-4266.
29. De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, Moser S, et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004; 173:5372-5380.
30. Kaech SM, Ahmed R. CD8 T cells remember with a little help. Science 2003; 300:263-265.
31. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002; 297:2060-2063.
32. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421:852-856.
33. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300:337-339.
34. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003; 300:339-342.
35. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4:225-234.
36. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005; 17:326-332.
37. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Kedl RM, Mattapallil JJ, et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA 2005; 102:15190-15194.
38. Bell I, Schaefer TM, Trible RP, Amedee A, Reinhart TA. Down-modulation of the costimulatory molecule, CD28, is a conserved activity of multiple SIV Nefs and is dependent on histidine 196 of Nef. Virology 2001; 283:148-158.
39. Schindler M, Munch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006; 125:1005-1067.
40. Schaefer TM, Bell I, Pfeifer ME, Ghosh M, Trible RP, Fuller CL, et al. The conserved process of TCR/CD3 complex down-modulation by SIV Nef is mediated by the central core, not endocytic motifs. Virology 2002; 302:106-122.
41. Betts MR, Yusim K, Koup RA. Optimal antigens for HIV vaccines based on CD8+ T response, protein length, and sequence variability. DNA Cell Biol 2002; 21:665-670.
42. Lichterfeld M, Yu XG, Cohen D, Addo MM, Malenfant J, Perkins B, et al. HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS 2004; 18:1383-1392.
43. Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, Addo MM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78:2187-2200.
44. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1:59-64. Erratum: Nat Med 1995; 1:598.
45. Patterson LJ, Malkevitch N, Zhao J, Peng B, Robert-Guroff M. Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef. DNA Cell Biol 2002; 21:627-635.
46. Hel Z, Tryniszewska E, Tsai WP, Johnson JM, Harrod R, Fullen J, et al. Design and in vivo immunogenicity of a polyvalent vaccine based on SIVmac regulatory genes. DNA Cell Biol 2002; 21:619-626.
47. Erfle V, Goebel FD, Guzman CA, LeGrand R. Vaccines based on Nef and on Nef/ΔV2 Env. Microbes Infect 2005; 7:1400-1404.
48. Voss G, Manson K, Montefiori D, Watkins DI, Heeney J, Wyand M, et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol 2003; 77: 1049-1058.
49. Cosma A, Nagaraj R, Bühler S, Hinkula J, Busch DH, Sutter G, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003; 22:21-29.
50. Harrer E, Bauerle M, Ferstl B, Chaplin P, Petzold B, Mateo L, et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 2005; 10:285-300.